Scarica l'app Stockscreener
9.56
4.50%
-0.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.01
Aprire:
$9.69
Volume 24 ore:
926.30K
Relative Volume:
0.35
Capitalizzazione di mercato:
$643.77M
Reddito:
$141.31M
Utile/perdita netta:
$-297.87M
Rapporto P/E:
-1.7726
EPS:
-5.3933
Flusso di cassa netto:
$-168.20M
1 W Prestazione:
-18.71%
1M Prestazione:
+2.03%
6M Prestazione:
+13.27%
1 anno Prestazione:
-25.20%
Intervallo 1D:
$9.50
$10.14
Intervallo di 1 settimana:
$9.6121
$11.80
Portata 52W:
$5.37
$18.22
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
9.56 | 643.77M | 141.31M | -297.87M | -168.20M | -5.3933 |
VRTX
Vertex Pharmaceuticals Inc
|
533.54 | 135.23B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.65 | 84.08B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.82 | 80.17B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
874.86 | 55.02B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
380.49 | 43.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Zacks Investment Research
Officer Che Austin proposes selling 2,200 shares valued at $22,836 in Ginkgo Bioworks (DNA). - Stock Titan
Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand - Yahoo Finance
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market - Zacks Investment Research
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market - Yahoo Finance
Ginkgo Bioworks Holdings Inc (DNA) PT Raised to $11 at TD Cowen - StreetInsider
Ginkgo Bioworks Holdings (NYSE:DNA) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 144 Ginkgo Bioworks Holdings For: 12 October By Investing.com - Investing.com South Africa
DNA Surges As Ginkgo Bioworks Lands Key AI Drug Deals - Timothy Sykes
What's Going on With Ginkgo Bioworks Stock on Friday? - Benzinga
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program - www.marketscreener.com
Ginkgo Bioworks Provides Autonomous Lab Access To National Science Foundation X-Labs Researchers, Contributing Cloud Lab Time And Protein Testing Services To $1.5 Billion Breakthrough Science Program - www.marketscreener.com
Researchers in a $1.5 billion science initiative will be able to use a robot lab remotely. - Stock Titan
Ginkgo Bioworks, Araceli Biosciences Add Cellular Imaging to Autonomous Lab - www.marketscreener.com
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop - Financial Times
DNAGinkgo Bioworks Holdings Inc. | News - OTC Markets
Ginkgo Bioworks to Provide Lab Access to NSF X-Labs Researchers - Yahoo Finance
Ginkgo Bioworks CFO Steven Coen sells $36,045 in stock - Investing.com
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know - Zacks Investment Research
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Ginkgo Bioworks CFO Steven Coen Sells 2,403 Shares Under Rule 10b5-1 Plan on October 5, 2026 - Kalkine Media
A planned share sale leaves Ginkgo Bioworks (DNA) CFO holding 49,448 shares directly. - Stock Titan
Ginkgo Bioworks: The Valuation Has Outrun The Business (NYSE:DNA) - Seeking Alpha
Officer Steven P. Coen proposes selling 2,403 Ginkgo Bioworks (NYSE: DNA) shares. - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Ginkgo Bioworks: Another Curious Rally (NYSE:DNA) - Seeking Alpha
AbbVie and Takeda can use AI models without revealing sequences to other members - Stock Titan
Ginkgo Bioworks (DNA) Slips 1.88% to $10.46, Testing the Middle of a Well-Defined RangeWide Range Bar - siam.in
(DNA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors - GlobeNewswire Inc.
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Zacks Investment Research
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - finance.yahoo.com
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains? - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges in the Biotech Sector - DirectorsTalk Interviews
Ginkgo Bioworks (DNA) officer may sell 2,200 shares - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Ginkgo Bioworks (NYSE: DNA) director sells 5,000 shares near $7.08 - Stock Titan
Ginkgo Bioworks And Eli Lilly And Company Enter Partnership To Integrate Ginkgo Datapoints With Lilly TuneLab - marketscreener.com
Director plans potential 5,000-share sale at Ginkgo Bioworks (NYSE: DNA) - Stock Titan
Up to $17.5M awarded to Ginkgo for medicines made for one patient - Stock Titan
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines - Investing News Network
BTIG cuts Ginkgo Bioworks stock price target on transition concerns By Investing.com - Investing.com Australia
DNAGinkgo Bioworks Holdings Inc Earnings - Finviz
BTIG cuts Ginkgo Bioworks stock price target on transition concerns By Investing.com - Investing.com South Africa
BTIG cuts Ginkgo Bioworks stock price target on transition concerns By Investing.com - Investing.com Canada
BTIG cuts Ginkgo Bioworks stock price target on transition concerns - Investing.com
Ginkgo Bioworks Holdings Inc (DNA) PT Lowered to $5 at BTIG - StreetInsider
(DNA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $5 - Moomoo
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ginkgo Bioworks Holdings Inc Azioni (DNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Canton Barry | 10% Owner |
Oct 19 '26 |
Sale |
10.14 |
18,803 |
190,719 |
356,329 |
| Che Austin | Officer |
Oct 19 '26 |
Proposed Sale |
10.38 |
2,200 |
22,836 |
0 |
| Kelly Jason R | Officer |
Oct 19 '26 |
Proposed Sale |
10.14 |
45,682 |
463,334 |
0 |
| Shetty Reshma P. | Officer |
Oct 19 '26 |
Proposed Sale |
10.14 |
22,369 |
226,880 |
0 |
| Che Austin | Officer |
Oct 19 '26 |
Proposed Sale |
10.14 |
16,058 |
162,870 |
0 |
| Canton Barry | Officer |
Oct 19 '26 |
Proposed Sale |
10.14 |
18,803 |
190,711 |
0 |
| Coen Steven P. | Officer |
Oct 19 '26 |
Proposed Sale |
10.14 |
766 |
7,769 |
0 |
| Kelly Jason R | See remarks |
Oct 19 '26 |
Sale |
10.14 |
45,682 |
463,353 |
129,065 |
| Shetty Reshma P. | See remarks |
Oct 19 '26 |
Sale |
10.14 |
18,803 |
190,719 |
356,329 |
| Shetty Reshma P. | See remarks |
Oct 19 '26 |
Sale |
10.14 |
22,369 |
226,889 |
453,951 |
0.36%
4.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):